Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
103.09
-0.18 (-0.17%)
At close: Nov 20, 2024, 4:00 PM
102.87
-0.22 (-0.21%)
Pre-market: Nov 21, 2024, 5:42 AM EST
Novartis AG Revenue
Novartis AG had revenue of $13.17B in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$49.94B
Revenue Growth
+8.92%
P/S Ratio
n/a
Revenue / Employee
$656,613
Employees
76,057
Market Cap
205.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
| Novo Nordisk | 40.47B |
NVS News
- 4 hours ago - Novartis: launch of Morphosys drug by could be 2027 or later - Reuters
- 5 hours ago - Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio - WSJ
- 6 hours ago - Novartis raises annual sales guidance until 2028 - Reuters
- 6 hours ago - Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth - GlobeNewsWire
- 1 day ago - Novartis ranks first in 2024 Access to Medicine Index - GlobeNewsWire
- 2 days ago - Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate - PRNewsWire
- 8 days ago - Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer - Business Wire
- 9 days ago - Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion - Market Watch